Skip to main content

Table 3 Effect of pramipexole versus ropinirole on cued recall according to patients’ pre-study dopamine agonist

From: Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment

Pre-study dopamine agonist Drug Condition Estimate: mean (SD) Difference (OFF–ON)
Mean (SD) 95% CI
PPX (n = 7) PPX OFF 0.366 (0.137) 0.034 (0.109) −0.067, 0.135
  ON 0.331 (0.140)   
RPR OFF 0.284 (0.152) 0.036 (0.194) −0.144, 0.215
  ON 0.249 (0.173)   
RPR (n = 9) PPX OFF 0.417 (0.162) 0.027 (0.084) −0.038, 0.091
  ON 0.390 (0.168)   
RPR OFF 0.360 (0.155) −0.016 (0.100) −0.092, 0.061
  ON 0.376 (0.147)   
  1. PPX pramipexole PR, RPR ropinirole, SD standard deviation, CI confidence interval